Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ipamorelin vs Mecasermin (Increlex)
An educational, source-based comparison of Ipamorelin and Mecasermin (Increlex) — how each peptide works, what it's researched for, and what to know before going deeper.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Ipamorelin | Ipamorelin, the first selective growth hormone secretagogue | European Journal of Endocrinology | 1998 | Characterized selectivity for GH release without affecting ACTH, cortisol, or prolactin. |
| Mecasermin (Increlex) | Mecasermin in severe primary IGFD | JCEM | 2007 | Improved height velocity over multi-year follow-up. |
Side-effect & safety grid
- Generally well tolerated in research; long-term human safety data are limited.
- Not FDA-approved.
- Use in sport is prohibited (WADA).
- FDA-approved.
- Hypoglycemia — must be taken with food.
- Tonsillar hypertrophy, intracranial hypertension reported.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Ipamorelin vs Mecasermin (Increlex) — Key differences
- Class: Ipamorelin is classified as Growth Hormone Axis, while Mecasermin (Increlex) is IGF-1 · Endocrine.
- Primary research focus: Ipamorelin — endogenous gh release without cortisol elevation; Mecasermin (Increlex) — severe primary igf-1 deficiency.
- Tag: Recovery · Sleep vs FDA-Approved · Endocrine.